123 related articles for article (PubMed ID: 8286212)
1. An enzyme-linked immunosorbent assay for hypoxia marker binding in tumours.
Raleigh JA; La Dine JK; Cline JM; Thrall DE
Br J Cancer; 1994 Jan; 69(1):66-71. PubMed ID: 8286212
[TBL] [Abstract][Full Text] [Related]
2. Distribution of the hypoxia marker CCI-103F in canine tumors.
Cline JM; Thrall DE; Rosner GL; Raleigh JA
Int J Radiat Oncol Biol Phys; 1994 Mar; 28(4):921-33. PubMed ID: 8138446
[TBL] [Abstract][Full Text] [Related]
3. Development of an ELISA for the detection of 2-nitroimidazole hypoxia markers bound to tumor tissue.
Raleigh JA; Zeman EM; Rathman M; LaDine JK; Cline JM; Thrall DE
Int J Radiat Oncol Biol Phys; 1992; 22(3):403-5. PubMed ID: 1310494
[TBL] [Abstract][Full Text] [Related]
4. ELISA quantification of CCI-103F binding in canine tumors prior to and during irradiation.
Thrall DE; McEntee MC; Cline JM; Raleigh JA
Int J Radiat Oncol Biol Phys; 1994 Feb; 28(3):649-59. PubMed ID: 8113108
[TBL] [Abstract][Full Text] [Related]
5. A comparison of oral and intravenous pimonidazole in canine tumors using intravenous CCI-103F as a control hypoxia marker.
Kleiter MM; Thrall DE; Malarkey DE; Ji X; Lee DY; Chou SC; Raleigh JA
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):592-602. PubMed ID: 16289910
[TBL] [Abstract][Full Text] [Related]
6. Quantification of CCI-103F labeling heterogeneity in canine solid tumors.
Cline JM; Rosner GL; Raleigh JA; Thrall DE
Int J Radiat Oncol Biol Phys; 1997 Feb; 37(3):655-62. PubMed ID: 9112464
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia marker labeling in tumor biopsies: quantification of labeling variation and criteria for biopsy sectioning.
Thrall DE; Rosner GL; Azuma C; McEntee MC; Raleigh JA
Radiother Oncol; 1997 Aug; 44(2):171-6. PubMed ID: 9288846
[TBL] [Abstract][Full Text] [Related]
8. Dynamic measurements of hexafluoromisonidazole (CCI-103F) retention in mouse tumours by 1H/19F magnetic resonance spectroscopy.
Jin GY; Li SJ; Moulder JE; Raleigh JA
Int J Radiat Biol; 1990 Dec; 58(6):1025-34. PubMed ID: 1978851
[TBL] [Abstract][Full Text] [Related]
9. Prediction of tumor radiosensitivity by hexafluoromisonidazole retention monitored by [1H]/[19F] magnetic resonance spectroscopy.
Li SJ; Jin GY; Moulder JE
Cancer Commun; 1991 May; 3(5):133-9. PubMed ID: 2043424
[TBL] [Abstract][Full Text] [Related]
10. Distribution of hypoxia and proliferation associated markers in spontaneous canine tumors.
Raleigh JA; Zeman EM; Calkins DP; McEntee MC; Thrall DE
Acta Oncol; 1995; 34(3):345-9. PubMed ID: 7779421
[TBL] [Abstract][Full Text] [Related]
11. Irradiation-dependent effects on tumor perfusion and endogenous and exogenous hypoxia markers in an A549 xenograft model.
Fokas E; Hänze J; Kamlah F; Eul BG; Lang N; Keil B; Heverhagen JT; Engenhart-Cabillic R; An H; Rose F
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1500-8. PubMed ID: 20637978
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical detection of a hypoxia marker in spontaneous canine tumours.
Cline JM; Thrall DE; Page RL; Franko AJ; Raleigh JA
Br J Cancer; 1990 Dec; 62(6):925-31. PubMed ID: 1701659
[TBL] [Abstract][Full Text] [Related]
13. Covalent binding of a fluorinated 2-nitroimidazole to EMT-6 tumors in Balb/C mice: detection by F-19 nuclear magnetic resonance at 2.35 T.
Raleigh JA; Franko AJ; Treiber EO; Lunt JA; Allen PS
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1243-5. PubMed ID: 3744946
[TBL] [Abstract][Full Text] [Related]
14. The relationship between proliferative and oxygenation status in spontaneous canine tumors.
Zeman EM; Calkins DP; Cline JM; Thrall DE; Raleigh JA
Int J Radiat Oncol Biol Phys; 1993 Nov; 27(4):891-8. PubMed ID: 8244820
[TBL] [Abstract][Full Text] [Related]
15. Development of an ELISA for the quantification of fibrin in canine tumours.
Raut S; McEvoy F; Gaffney PJ
Thromb Res; 1999 Oct; 96(1):11-7. PubMed ID: 10554080
[TBL] [Abstract][Full Text] [Related]
16. Description of a spheroid model for the study of radiation and chemotherapy effects on hypoxic tumor cell populations.
Moore DH; Rouse MB; Massenburg GS; Zeman EM
Gynecol Oncol; 1992 Oct; 47(1):44-7. PubMed ID: 1427399
[TBL] [Abstract][Full Text] [Related]
17. Orally administered pimonidazole to label hypoxic tumor cells.
Bennewith KL; Raleigh JA; Durand RE
Cancer Res; 2002 Dec; 62(23):6827-30. PubMed ID: 12460894
[TBL] [Abstract][Full Text] [Related]
18. Longevity of pimonidazole adducts in spontaneous canine tumors as an estimate of hypoxic cell lifetime.
Azuma C; Raleigh JA; Thrall DE
Radiat Res; 1997 Jul; 148(1):35-42. PubMed ID: 9216616
[TBL] [Abstract][Full Text] [Related]
19. Use of 2-nitroimidazoles as bioreductive markers for tumour hypoxia.
Hodgkiss RJ
Anticancer Drug Des; 1998 Sep; 13(6):687-702. PubMed ID: 9755725
[TBL] [Abstract][Full Text] [Related]
20. Comparative pharmacokinetics, biodistribution, metabolism and hypoxia-dependent uptake of [18F]-EF3 and [18F]-MISO in rodent tumor models.
Mahy P; De Bast M; de Groot T; Cheguillaume A; Gillart J; Haustermans K; Labar D; Grégoire V
Radiother Oncol; 2008 Dec; 89(3):353-60. PubMed ID: 18649964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
